Cargando…
Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas
INTRODUCTION: Malignant gliomas are a heterogeneous group of primary central nervous system neoplasms that represent less than 2% of all cancers yet carry a significant burden to society. They are frequently associated with considerable and progressive neurological disability and are ultimately intr...
Autores principales: | Omar, Ayman I, Mason, Warren P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899776/ https://www.ncbi.nlm.nih.gov/pubmed/20694068 |
Ejemplares similares
-
Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
por: Fujimaki, Takamitsu, et al.
Publicado: (2007) -
Podocalyxin regulates astrocytoma cell invasion and survival against temozolomide
por: WU, HAO, et al.
Publicado: (2013) -
Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
por: Gwak, Ho-Shin, et al.
Publicado: (2013) -
Development of Aplastic Anemia during Treatment of Anaplastic Astrocytoma with Temozolomide
por: Khaddour, Karam, et al.
Publicado: (2020) -
Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
por: Weller, Jonathan, et al.
Publicado: (2022)